Advanced Cancer Therapeutics CEO to Present Preclinical Data on Cancer Metabolism Drug
at MidAmerica Healthcare Venture Forum
Louisville, KY - October 19, 2011 - Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that Randall B. Riggs, President & CEO, has been selected to present at the 9th Annual MidAmerica Healthcare Venture Forum to be held at the Louisville Marriott Downtown in Louisville, Kentucky, November 8, 2011 at 2:33 p.m. ACT is one of 27 companies chosen to present at the Forum which unites leading Midwest and coastal investors with corporate business development representatives to syndicate deal flow and facilitate investment opportunities in promising Midwest based healthcare start-ups.
Mr. Riggs will discuss the strides taken by ACT to advance tomorrow’s discoveries in cancer treatment, with a particular focus on PFK-158, ACT’s novel and potent small molecule clinical candidate in the area of cancer metabolism. PFK-158 is a small molecule inhibitor which targets a cancer cell’s ability to consume sugar/glucose, a key fuel source in cancer cell growth and metastasis. PFK-158 is currently undergoing IND-enabling studies in preparation for Phase I human clinical trials.
About Advanced Cancer Therapeutics (ACT):
ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Don Miller, the Brown Cancer Center employs over fifty scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com.
Contact:
Randall B. Riggs, President & CEO
Advanced Cancer Therapeutics
Phone: (502) 345-8911
Email: rriggs@advancedact.com
FOR IMMEDIATE RELEASE